Stockscreener 앱 받기
158.88
0.64%
1.01
시간 외 거래:
158.88
Axsome Therapeutics Inc 주식(AXSM)의 최신 뉴스
Axsome Therapeutics’ Q4 numbers beat Wall Street expectations: Analyst sees over 23% upside for stock - MSN
Superstring Capital's New Axsome Therapeutics Position: A $6.84M Biopharma InvestmentNews and Statistics - IndexBox
This New $7 Million Bet Targets a CNS Drug Maker With Phase 3 Trial Underway and 27% Stock Gain - AOL.com
Wolfe Research initiates coverage of Axsome Therapeutics (AXSM) with outperform recommendation - MSN
Axsome shares slip despite fourth-quarter earnings beat and strong revenue growth - MSN
(AXSM) Risk Channels and Responsive Allocation - Stock Traders Daily
Axsome Therapeutics CEO Completes Planned $6 Million Options Sale Ahead of Pivotal FDA Decision - AOL.com
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Axsome Therapeutics, Inc. $AXSM Shares Purchased by Eventide Asset Management LLC - MarketBeat
A Look At Axsome Therapeutics (AXSM) Valuation As Legal Probe And FDA Decision Draw Investor Focus - simplywall.st
Profit Review: How much upside does Axsome Therapeutics Inc have2026 Outlook & Precise Swing Trade Entry Alerts - baoquankhu1.vn
AXSM's 2025 Revenue Growth Primarily Fueled by Auvelity: What Does the Future Hold? - Bitget
AXSM's 2025 Revenue Surge Largely Driven by Auvelity: What's Ahead? - TradingView
RBC Capital reiterates Axsome Therapeutics stock rating at Outperform By Investing.com - Investing.com Canada
Axsome Therapeutics Highlights Auvelity’s $500M+ Run, FDA Catalyst and Late-Stage Pipeline at Conference - MarketBeat
Is It Time To Revisit Axsome Therapeutics (AXSM) After Recent Share Price Weakness - simplywall.st
Johnson Fistel, PLLP Investigates Claims on Behalf of - GlobeNewswire
Axsome Therapeutics at The Citizens Life Sciences Conference: Strategic Growth Plans - Investing.com Canada
AXSM: Major 2026 catalysts include Auvelity's PDUFA for Alzheimer's agitation and field force expansion - TradingView
AXSM: April 2026 PDUFA for Auvelity in Alzheimer's agitation is a key near-term catalyst - TradingView
A Look At Axsome Therapeutics (AXSM) Valuation After Priority Review And 2025 Revenue Growth - Yahoo Finance
2 Under-the-Radar Stocks to Buy and Hold - The Globe and Mail
Axsome Therapeutics Highlights Auvelity Sales Push, April 30 PDUFA, and Symbravo Launch Updates - MarketBeat
Inceptionr LLC Invests $1.05 Million in Axsome Therapeutics, Inc. $AXSM - MarketBeat
Axsome Therapeutics at Leerink Conference: Strategic Growth and Challenges By Investing.com - Investing.com Canada
AXSM: Auvelity accelerates growth and pipeline advances with major expansions and new clinical programs - TradingView
Axsome Therapeutics, Inc. $AXSM is Rhenman & Partners Asset Management AB's 8th Largest Position - MarketBeat
(AXSM) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Axsome Therapeutics, Inc. $AXSM Shares Sold by Quantbot Technologies LP - MarketBeat
Axsome Therapeutics touts AUVELITY $155M quarter, doubles salesforce ahead of April FDA decision - MarketBeat
Royce & Associates LP Raises Position in Axsome Therapeutics, Inc. $AXSM - MarketBeat
Axsome Therapeutics, Inc. $AXSM Shares Sold by Intech Investment Management LLC - MarketBeat
Assessing Axsome Therapeutics (AXSM) Valuation After Earnings Momentum And New Phase 3 Trial Launch - simplywall.st
AXSM Earnings History & Surprises | EPS & Revenue Results | AXSOME THERAPEUTICS INC (NASDAQ:AXSM) - ChartMill
Axsome Therapeutics, Inc. $AXSM Position Boosted by TD Asset Management Inc - MarketBeat
Should Axsome’s Revenue Jump and SUNOSI IP Win Require Action From Axsome Therapeutics (AXSM) Investors? - simplywall.st
AXSM: Robust late-stage pipeline and sales force expansion drive growth across CNS and pain markets - TradingView
AXSM: AUVELITY and pipeline assets drive growth, with key FDA decisions and launches ahead - TradingView
Axsome Therapeutics (AXSM): Analyst Consensus Highlights 35% Potential Upside for This Biotech Innovator - DirectorsTalk Interviews
Axsome Therapeutics Aktie: Wachstumskurs bestätigt - sharewise.com
DNB Asset Management AS Increases Stock Position in Axsome Therapeutics, Inc. $AXSM - MarketBeat
Axsome Therapeutics, Inc. $AXSM Shares Bought by JPMorgan Chase & Co. - MarketBeat
Axsome Therapeutics, Inc. (AXSM): A Bull Case Theory - Bitget
Axsome Explores Solriamfetol In Phase 3 CLARITY Trial For MDD Subset - Sahm
Citigroup Inc. Boosts Position in Axsome Therapeutics, Inc. $AXSM - MarketBeat
Axsome Therapeutics (NASDAQ:AXSM) COO Sells $5,726,990.64 in Stock - MarketBeat
Mark Coleman Sells 25,000 Shares of Axsome Therapeutics (NASDAQ:AXSM) Stock - MarketBeat
Axsome (NASDAQ: AXSM) CEO awarded 54,623 RSUs vesting by 2030 - Stock Titan
[Form 4] Axsome Therapeutics, Inc. Insider Trading Activity - Stock Titan
Axsome Therapeutics (AXSM) director completes 25,000-share 10b5-1 sale - Stock Titan
Axsome Therapeutics Executives Sell Shares Worth Over $9.7 Million - TradingView
Axsome Opens CLARITY Trial As Solriamfetol Targets Underserved MDD Patients - Yahoo Finance
Axsome’s $7.75 Million Investor Settlement Gets Court Sendoff - Bloomberg Law News
Q1 EPS Estimate for Axsome Therapeutics Reduced by Analyst - MarketBeat
Axsome Therapeutics’ Q4 Numbers Beat Wall Street Expectations: Analyst Sees Over 23% Upside For Stock - Stocktwits
AXSM (NASDAQ: AXSM) affiliate to sell 35,378 Class A shares via cashless exercise - Stock Titan
Smart Money Is Betting Big In AXSM OptionsAxsome Therapeutics (NASDAQ:AXSM) - Benzinga
Psychedelic Medicine Advances: Here Are Five Companies Targeting CNS Disorders - Benzinga
1.20%
0.06%
자본화:
|
볼륨(24시간):